G1 Therapeutics (GTHX) Stock Price, News & Analysis

Company Overview

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Key Stats

• Today's Range: $7.15 to $7.15
• 50-Day Range: $7.08 to $7.15
• 52-Week Range: $1.08 to $7.19
• Volume: N/A
• Average Volume: 1.70 million shs
• Market Capitalization: $373.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

G1 Therapeutics Stock Analysis - MarketRank™

G1 Therapeutics scored higher than 8% of companies evaluated by MarketBeat, and ranked 931st out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

G1 Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

G1 Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for G1 Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of G1 Therapeutics is -11.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of G1 Therapeutics is -11.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

G1 Therapeutics has a P/B Ratio of 10.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GTHX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

G1 Therapeutics does not currently pay a dividend.

Dividend Growth

G1 Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -2.45

Short Interest

There is no current short interest data available for GTHX.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for GTHX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, G1 Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.11% of the stock of G1 Therapeutics is held by insiders.

Percentage Held by Institutions

Only 24.21% of the stock of G1 Therapeutics is held by institutions.

GTHX Stock Analysis - Frequently Asked Questions

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) announced its earnings results on Wednesday, May, 1st. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.01. The firm had revenue of $14.48 million for the quarter, compared to the consensus estimate of $15.21 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 136.98% and a negative net margin of 76.93%.

When did G1 Therapeutics IPO?

G1 Therapeutics (GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' top institutional shareholders include Ikarian Capital LLC and Belvedere Trading LLC. Insiders that own company stock include John E (Jack) Jr Bailey, John W V Umstead, Rajesh Malik, Terry L Murdock, Mark A Velleca, Andrew Perry, Monica R Thomas, Jennifer K Moses and James S Hanson.
View institutional ownership trends.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that G1 Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Moderna (MRNA), Novavax (NVAX), Pfizer (PFE), NVIDIA (NVDA) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 5/01/2024
• Today: 11/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GTHX
• CUSIP: N/A
• CIK: 1560241
• Web: www.g1therapeutics.com
• Phone: (919) 213-9835
• Fax: 919-741-5830
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.00
• High Stock Price Target: $6.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: -44.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-47,970,000.00
• Net Margins: -76.93%
• Pretax Margin: -73.83%
• Return on Equity: -136.98%
• Return on Assets: -39.33%

Debt

• Debt-to-Equity Ratio: 1.34
• Current Ratio: 2.48
• Quick Ratio: 2.12

Sales & Book Value

• Annual Sales: $58.20 million
• Price / Sales: 6.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.68 per share
• Price / Book: 10.51

Miscellaneous

• Outstanding Shares: 52,281,000
• Free Float: 49,087,000
• Market Cap: $373.81 million
• Optionable: Optionable
• Beta: 1.66